• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease.

作者信息

Karkoska Kristine, Quinn Charles T, Clapp Kelly, McGann Patrick T

机构信息

Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.

出版信息

Am J Hematol. 2020 Dec;95(12):E338-E339. doi: 10.1002/ajh.26002. Epub 2020 Sep 30.

DOI:10.1002/ajh.26002
PMID:32945013
Abstract
摘要

相似文献

1
Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease.一名患有镰状细胞病的青少年对crizanlizumab发生严重的输液相关反应。
Am J Hematol. 2020 Dec;95(12):E338-E339. doi: 10.1002/ajh.26002. Epub 2020 Sep 30.
2
Crizanlizumab: First Approval.西尼兰单抗：首次获批
Drugs. 2020 Jan;80(1):79-84. doi: 10.1007/s40265-019-01254-2.
3
Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis.西利单抗治疗镰状细胞病患者亚组疼痛危象的效果：SUSTAIN 研究分析。
Am J Hematol. 2019 Jan;94(1):55-61. doi: 10.1002/ajh.25308. Epub 2018 Nov 25.
4
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.克立硃单抗用于预防镰状细胞病的疼痛危象
N Engl J Med. 2017 Feb 2;376(5):429-439. doi: 10.1056/NEJMoa1611770. Epub 2016 Dec 3.
5
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease.西利单抗治疗镰状细胞病患者的药代动力学、药效学、安全性和疗效。
Blood Adv. 2023 Mar 28;7(6):943-952. doi: 10.1182/bloodadvances.2022008209.
6
Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel.镰状细胞病（SCD）患者接受crizanlizumab 治疗时输注相关反应（IRR）管理的专家共识：RAND/UCLA 改良 Delphi 小组。
Ann Hematol. 2024 Jun;103(6):1909-1917. doi: 10.1007/s00277-024-05736-6. Epub 2024 Apr 20.
7
Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?克立硃单抗与镰状细胞病：药物的批准状态何时应被撤销？
Am J Hematol. 2024 Jun;99(6):1016-1018. doi: 10.1002/ajh.27275. Epub 2024 Feb 26.
8
Real-world experience of patients with sickle cell disease treated with crizanlizumab.镰状细胞病患者使用crizanlizumab 治疗的真实世界经验。
J Investig Med. 2024 Feb;72(2):242-247. doi: 10.1177/10815589231220592. Epub 2024 Jan 8.
9
A critical evaluation of crizanlizumab for the treatment of sickle cell disease.对治疗镰状细胞病的 crizanlizumab 的评价。
Expert Rev Hematol. 2022 Jan;15(1):5-13. doi: 10.1080/17474086.2022.2023007. Epub 2021 Dec 30.
10
Crizanlizumab in vaso-occlusive crisis caused by sickle cell disease.西尼莫司单抗治疗镰状细胞病所致血管阻塞性危象
Drugs Today (Barc). 2020 Nov;56(11):705-714. doi: 10.1358/dot.2020.56.11.3178111.

引用本文的文献

1
Accelerated drug approvals and patient trust: impact of voxelotor and crizanlizumab for sickle cell disease.加速药物批准与患者信任：伏索利洛和克瑞扎珠单抗对镰状细胞病的影响
Blood Adv. 2025 Jun 10;9(11):2857-2862. doi: 10.1182/bloodadvances.2025015822.
2
Fostering a healthier generation of children with sickle cell disease through advancements in care.通过护理方面的进步，培养出更健康的镰状细胞病患儿一代。
Pediatr Res. 2024 Sep 13. doi: 10.1038/s41390-024-03566-w.
3
Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel.
镰状细胞病（SCD）患者接受crizanlizumab 治疗时输注相关反应（IRR）管理的专家共识：RAND/UCLA 改良 Delphi 小组。
Ann Hematol. 2024 Jun;103(6):1909-1917. doi: 10.1007/s00277-024-05736-6. Epub 2024 Apr 20.
4
Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report.一名镰状细胞病患者发生严重的克立硐珠单抗输注相关血管闭塞性危机后的短期和长期随访及额外获益：病例报告
Front Med (Lausanne). 2022 Nov 29;9:1048571. doi: 10.3389/fmed.2022.1048571. eCollection 2022.
5
Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.比较L-谷氨酰胺、伐地考昔和克立唑单抗在降低镰状细胞病血管闭塞性危象发生率方面的安全性和有效性：一项系统评价。
Cureus. 2022 May 11;14(5):e24920. doi: 10.7759/cureus.24920. eCollection 2022 May.
6
Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease.克立硃单抗预防镰状细胞病血管闭塞性疼痛危象
J Pharm Technol. 2021 Aug;37(4):209-215. doi: 10.1177/87551225211008460. Epub 2021 Apr 19.
7
Research in Sickle Cell Disease: From Bedside to Bench to Bedside.镰状细胞病研究：从床边到 bench 再回到床边 。 注：这里“bench”直译为“实验台”，整体表述强调了镰状细胞病研究从临床实践出发，到实验室研究，再应用回临床实践的过程 。
Hemasphere. 2021 Jun 1;5(6):e584. doi: 10.1097/HS9.0000000000000584. eCollection 2021 Jun.
8
P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab.P-选择素阻断剂在镰状细胞病疼痛性血管闭塞危象治疗中的应用：聚焦克立硐珠单抗
J Pain Res. 2021 Mar 30;14:849-856. doi: 10.2147/JPR.S278285. eCollection 2021.
9
P-selectin deficiency promotes liver senescence in sickle cell disease mice.P 选择素缺乏促进镰状细胞病小鼠肝脏衰老。
Blood. 2021 May 13;137(19):2676-2680. doi: 10.1182/blood.2020009779.